Ligand Non Operating Income Net Other from 2010 to 2024
| LGND Stock | USD 77.82 1.08 1.37% |
Non Operating Income Net Other | First Reported 2011-06-30 | Previous Quarter 41.6 M | Current Value 5.4 M | Quarterly Volatility 19.7 M |
Check Ligand Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ligand Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 37.4 M, Interest Expense of 623.2 K or Total Revenue of 101.8 M, as well as many indicators such as Price To Sales Ratio of 9.2, Dividend Yield of 0.42 or PTB Ratio of 1.67. Ligand financial statements analysis is a perfect complement when working with Ligand Pharmaceuticals Valuation or Volatility modules.
Ligand | Non Operating Income Net Other |
Latest Ligand Pharmaceuticals' Non Operating Income Net Other Growth Pattern
Below is the plot of the Non Operating Income Net Other of Ligand Pharmaceuticals Incorporated over the last few years. It is Ligand Pharmaceuticals' Non Operating Income Net Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ligand Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Non Operating Income Net Other | 10 Years Trend |
|
Non Operating Income Net Other |
| Timeline |
Ligand Non Operating Income Net Other Regression Statistics
| Arithmetic Mean | 725,936 | |
| Coefficient Of Variation | 2,778 | |
| Mean Deviation | 13,441,492 | |
| Median | (3,660,000) | |
| Standard Deviation | 20,168,485 | |
| Sample Variance | 406.8T | |
| Range | 81.6M | |
| R-Value | (0.14) | |
| Mean Square Error | 429.1T | |
| R-Squared | 0.02 | |
| Significance | 0.61 | |
| Slope | (643,829) | |
| Total Sum of Squares | 5694.7T |
Ligand Non Operating Income Net Other History
About Ligand Pharmaceuticals Financial Statements
Ligand Pharmaceuticals stakeholders use historical fundamental indicators, such as Ligand Pharmaceuticals' Non Operating Income Net Other, to determine how well the company is positioned to perform in the future. Although Ligand Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ligand Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Ligand Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ligand Pharmaceuticals Incorporated. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Operating Income Net Other | -13.8 M | -13.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Ligand Stock
When determining whether Ligand Pharmaceuticals is a strong investment it is important to analyze Ligand Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ligand Pharmaceuticals' future performance. For an informed investment choice regarding Ligand Stock, refer to the following important reports:Check out the analysis of Ligand Pharmaceuticals Correlation against competitors. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ligand Pharmaceuticals. If investors know Ligand will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ligand Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.032 | Earnings Share 5.35 | Revenue Per Share 6.774 | Quarterly Revenue Growth (0.30) | Return On Assets (0) |
The market value of Ligand Pharmaceuticals is measured differently than its book value, which is the value of Ligand that is recorded on the company's balance sheet. Investors also form their own opinion of Ligand Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ligand Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ligand Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ligand Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ligand Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ligand Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ligand Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.